ASCO 2017 - NHL: 82% ORR with axicabtagene ciloleucel in phase 1/2 ZUMA-1 trial

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Axi-cel (axicabtagene ciloleucel; KTE-C19) induced an objective response rate (ORR) of 82% in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL) in this phase 1/2 trial, and the response is ongoing in 44% of patients almost 9 mo later.

Why this matters

  • Outcome...